Abstract: In recent years, the targeted therapy and immune checkpoingt therapy for gastric cancer have achieved much progress. Breakthroughs have been made in the research and application of targeted therapies, and progress has been made towards precision. Immunotherapy has also shown great therapeutic potential in gastric cancer. Several checkpoint immunosuppressor have been approved for marketing, and many clinical trials on new drugs are also ongoing. At present, combining basic research with clinical treatment and applying laboratory results to clinical treatment as soon as possible are still the tasks that we need to work hard.